{"id":"oral-estazolam-medication","safety":{"commonSideEffects":[{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dependence/tolerance with prolonged use"},{"rate":null,"effect":"Cognitive impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Estazolam binds to benzodiazepine receptors on GABA-A channels in the central nervous system, increasing chloride ion influx and neuronal hyperpolarization. This potentiation of GABAergic inhibition reduces neuronal excitability, leading to sedative, anxiolytic, and hypnotic effects. The drug is used primarily for short-term management of insomnia.","oneSentence":"Estazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, promoting sedation and sleep.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:44.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (short-term management of sleep initiation and maintenance)"}]},"trialDetails":[{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT05452577","phase":"NA","title":"Treatment of Chronic Insomnia According to Yin Yang Theory and Its Correlation With Circadian Rhythm","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-01-22","conditions":"Chronic Insomnia, Circadian Rhythm, Traditional Chinese Medicine","enrollment":187},{"nctId":"NCT06258226","phase":"NA","title":"A Randomized Controlled Trial of Auricular Acupressure in Treating Estazolam-dependent Insomnia","status":"UNKNOWN","sponsor":"Wenzhou Central Hospital","startDate":"2024-07-01","conditions":"Estazolam-dependent Insomnia","enrollment":108},{"nctId":"NCT03997058","phase":"PHASE4","title":"Observation on the Effect of Auricular Acupoint Pressing on Insomnia and Adverse Events in MHD","status":"UNKNOWN","sponsor":"The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","startDate":"2019-03-01","conditions":"Renal Dialysis, Sleep Initiation and Maintenance Disorders","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oral estazolam medication","genericName":"Oral estazolam medication","companyName":"The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine","companyId":"the-first-affiliated-hospital-guangzhou-university-of-traditional-chinese-medici","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, promoting sedation and sleep. Used for Insomnia (short-term management of sleep initiation and maintenance).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}